Larvol Delta - Fluzoparib-Combined-With-Camrelizumab-for-Neoadjuvant-Treatment-of-Embryogenic-BRCA-Mutation-HER2-Negative-Breast-Cancer-an-Open-Single-Arm-Multicenter-Study

AiRuiYi (fluzoparib) - Jiangsu Hengrui Pharma

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://clinicaltrials.gov/ct2/show/NCT05576389

Jul 22, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next